| Company Name: |
Guangzhou PI PI Biotech Inc
|
| Tel: |
+86-020-81716320 +86-13602409664 |
| Email: |
Sales@pipitech.com |
| Products Intro: |
Product Name:Sofosbuvir Impurity 49 (GS-566500)-13C-d3
CAS:1256490-46-6
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Sales@pipitech.com Remarks:(2S)-2-(((((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoic-13CD3 Acid; O-Desisopropyl O-Desphenyl Sofosbuvir-13C,D3
|
| Company Name: |
Shanghai Biopharmaleader Co., Ltd.
|
| Tel: |
+86 18721201413 |
| Email: |
sales@biopharmaleader.com |
| Products Intro: |
Product Name:PSI 352707-13C,D3
CAS:1256490-46-6
Purity:98%HPLC Package:10g,100g
|
| Company Name: |
PI & PI BIOTECH INC.
|
| Tel: |
020-81716320 17788709170 |
| Email: |
Sales@pipitech.com |
| Products Intro: |
CAS:1256490-46-6
|
|
| | PSI 352707-13C,D3 Basic information |
| Product Name: | PSI 352707-13C,D3 | | Synonyms: | PSI 352707-13C,D3;UOYKQCZOTUPGRY-ARUJFWOBSA-N;GS-566500 13CD3;Sofosbuvir metabolite GS-566500 13CD3Q: What is
Sofosbuvir metabolite GS-566500 13CD3 Q: What is the CAS Number of
Sofosbuvir metabolite GS-566500 13CD3 Q: What is the storage condition of
Sofosbuvir metabolite GS-566500 13CD3 Q: What are the applications of
Sofosbuvir metabolite GS-566500 13CD3;Sofosbuvir Impurity 49 (GS-566500)-13C-d3;(2S)-2-(((((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoic-13CD3 Acid;O-Desisopropyl O-Desphenyl Sofosbuvir-13C,D3;SofosbuvirImpurity49-13C-d3DitriethylamineSalt | | CAS: | 1256490-46-6 | | MF: | C13H16D3FN3O9P | | MW: | 415.304309534 | | EINECS: | | | Product Categories: | | | Mol File: | 1256490-46-6.mol |  |
| | PSI 352707-13C,D3 Chemical Properties |
| | PSI 352707-13C,D3 Usage And Synthesis |
| Uses | P839645-13CD3 is a labelled metabolite of PSI-7977 (P839640), a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. |
| | PSI 352707-13C,D3 Preparation Products And Raw materials |
|